Samsrita Labs Ltd (SAMSRITA) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Samsrita Labs Ltd on NSE and BSE, with an AI summary of each filing.
Samsrita Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2026 ,inter alia, to consider and approve 1. unaudited Standalone and Consolidated ....
Intimation · 11 Nov 2026, 5:30 am
Samsrita Labs Schedules Board Meeting to Consider Q2 FY27 Results Samsrita Labs Limited announced that its Board of Directors will meet on 11th Nov'26 to consider and approve the un-audited standalone and consolidated financial results, along with the Limited Review Report, for the quarter and half-year ended 30th Sep'26. Additionally, the trading window for dealing in company securities has been closed from 1st Oct'26 and will remain closed until 48 hours following the declaration of the financial results for all designated persons and insiders.
Scrutinizer Report
Extra Ordinary General Meeting · 27 Oct 2026, 12:27 am
Samsrita Labs Shareholders Approve Key Material Related Party Transactions at EGM Samsrita Labs Limited announced the scrutinizer’s report for its EGM held on 26th Oct'26, confirming that all three proposed ordinary resolutions were approved by shareholders with a 99.27% majority (4,195,559 votes in favor versus 30,769 votes against). Key approvals include material related party transactions with S Labs Hygiene Care Private Limited, an investment via subscription to Compulsorily Convertible Preference Shares (CCPS) in S Labs Hygiene Care, and availing an unsecured loan from Mr. Ravikanth Naga Pattabhi Chopperla, Non-Executive Director.
outcome of EGM held on 26.10.2026
Extra Ordinary General Meeting · 27 Oct 2026, 12:09 am
Samsrita Labs Shareholders Approve Key Related-Party Transactions at EGM Samsrita Labs Limited approved all three ordinary resolutions at its Extra-Ordinary General Meeting held on 26th Oct'26. Shareholders approved material related-party transactions with S Labs Hygiene Care Private Limited, including an investment via subscription to Compulsorily Convertible Preference Shares (CCPS). Additionally, members sanctioned availing an unsecured loan from Mr interrupted Ravikanth Naga Pattabhi Chopperla, Non-Executive Director. Across all three resolutions, 4,226,328 votes were polled—representing 18.58% of total outstanding shares and 24.91% of public non-institutional holdings—with 99.27% voting in favour (4,195,559 votes) and 0.73% against.
Intimation regarding Alteration of Memorandum of Association of the Company
Others (Uncategorized) · 10 Oct 2026, 8:55 pm
ROC Approves Samsrita Labs MOA Alteration for Expansion into Veterinary and Pet Healthcare The Registrar of Companies (ROC) approved the alteration to the Main Objects Clause of Samsrita Labs Limited's Memorandum of Association via an approval letter dated 7th Oct'26. The amendment enables the company to expand into veterinary care, diagnostics, treatment, preventive healthcare, rehabilitation, grooming, nutrition, and wellness services for pets and companion animals, complementing its existing business activities.
Submission of Notice of EGM of the Company to be held on 26.10.2026
Extra Ordinary General Meeting · 03 Oct 2026, 8:46 pm
Samsrita Labs Convenes EGM for Material Related Party Transactions Samsrita Labs scheduled an EGM on 26th Oct'26 (e-voting cut-off: 19th Oct'26) seeking shareholder approval for key related party transactions. Proposed items include selling pet care goods up to Rs 25.00 crore to S Labs Hygiene Care Pvt Ltd, investing up to Rs 1.00 crore via Compulsorily Convertible Preference Shares (CCPS) in S Labs Hygiene Care utilizing prior preferential issue proceeds, and availing an unsecured loan up to Rs 1.00 crore at 9.00% p.a. from Non-Executive Director Ravikanth Chopperla to support working capital.
Outcome of Board Meeting held on 28.09.2026
Others (Uncategorized) · 28 Sept 2026, 11:09 pm
Samsrita Labs Approves Related-Party Transactions and Working Capital Loan Samsrita Labs' board approved an investment of up to ₹1.00 crore in S Labs Hygiene Care via Compulsory Convertible Preference Shares by 30th Jun'27 to expand into pet care and hygiene. It also approved related-party sale transactions worth up to ₹25.00 crore with S Labs Hygiene Care and an unsecured working capital loan of up to ₹1.00 crore from Non-Executive Director Ravikanth Naga Pattabhi Chopperla. All proposals are subject to shareholder approval at the Extra-Ordinary General Meeting scheduled for 26th Oct'26.
Announcement under Regulation 30 (LODR) - Newspaper Publication
Others (Uncategorized) · 14 Aug 2026, 4:20 pm
Samsrita Labs Reports Q1 FY27 Unaudited Financial Results Samsrita Labs published its unaudited standalone and consolidated financial results for the quarter ended 30th Jun'26. The results were approved by the Board of Directors on 13th Aug'26. As per the advertisement, detailed results, including a limited review report, are available on the websites of the BSE (539267) and MSEI (SAMSRITA), and on the company's website. The filing serves as a notification under SEBI's Regulation 47, but does not contain the actual financial numbers, which are published separately.
Statement of Deviation or Variation for the quarter ended 30.06.2026
Others (Uncategorized) · 13 Aug 2026, 9:51 pm
Samsrita Labs: No Deviation in Use of Preferential Issue Proceeds Samsrita Labs confirms no deviation in the use of proceeds from its preferential issue for the quarter ended 30 Jun '26. The company raised INR 339.10 lakhs on 18 Jul '25. As of 30 Jun '26, it has utilized INR 225.61 lakhs (66.5%) of the total funds. Utilizations include INR 52.10 lakhs for working capital, INR 88.31 lakhs for loan repayment, INR 28.62 lakhs for new projects, and INR 56.58 lakhs for general corporate purposes, all in line with original objects.
Outcoem of Board Meeting held on 13.08.2026
Outcome · 13 Aug 2026, 9:39 pm
Samsrita Labs Q1 FY27 Results: Consolidated Loss Widens Despite Associate Profits Samsrita Labs reported standalone results for Q1 FY27 ending 30 Jun'26, showing a net loss of ₹31.47 Lakhs, widening from a loss of ₹27.66 Lakhs YoY. Total revenue was nil. On a consolidated basis, the net loss for the quarter was ₹18.87 Lakhs, impacted by a ₹12.60 Lakhs profit share from associate companies. This compares to a consolidated loss of ₹52.55 Lakhs in the prior year period. Total consolidated expenses stood at ₹31.47 Lakhs. Basic EPS was negative at ₹(0.08) versus ₹(0.06) QoQ.
un-audited Financial Results for the quarter ended 30.06.2026
Financial Result · 13 Aug 2026, 9:35 pm
Samsrita Labs Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakh) ■ Revenue: 0.0 (-100.0% QoQ) ■ EBITDA: -31.4 (-109.1% QoQ) ■ EBITDA Margin (%): 0.0 (Loss to Profit QoQ) ■ PAT: -18.9 (+60.8% QoQ) ■ EPS (INR): -0.08 (-33.3% QoQ)
Scrutinizer''s Report for the 30th AGM held on 10.08.2026
Annual General Meeting · 10 Aug 2026, 11:21 pm
Outcome of 30th Annual General Meeting held on 10.08.2026
Annual General Meeting · 10 Aug 2026, 11:17 pm
Samsrita Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 ,inter alia, to consider and approve un-audited Financial Results ....
Intimation · 13 Aug 2026, 5:30 am
Samsrita Labs Board Meeting on Aug 13, 2026 for Q1 FY27 Results Samsrita Labs Limited (BSE: 539267) has scheduled a Board of Directors meeting on 13 Aug'26. The primary agenda is to consider and approve the un-audited standalone and consolidated financial results for the first quarter ending 30 Jun'26. The Board will also take note of the Limited Review Report from the statutory auditor for the same period.
Annual Report for FY 2025-26 of the Company
Others (Uncategorized) · 18 Jul 2026, 8:22 pm
Notice of AGM for the FY 2025-26 scheduled to be held on 10.08.2026
Annual General Meeting · 18 Jul 2026, 8:17 pm
Update on the Outcome of Board Meeting held on 04.07.2026
Outcome · 08 Jul 2026, 5:22 pm
Samsrita Labs Proposes 50% Share Capital Reduction to Offset Losses Samsrita Labs' Board has approved a capital reduction scheme to set off accumulated losses. The company will cancel 1,13,74,855 equity shares (₹10 face value) on a pro-rata basis, reducing paid-up capital by 50% from ₹22.75 crore to ₹11.37 crore. This will set off ₹11.37 crore against total accumulated losses and share premium of ₹11.58 crore. The restructuring aims to improve net worth and present a truer financial position. Existing shareholding percentages will remain unchanged, with no benefit to promoters.
Update on the Outcome of Board Meeting held on 04.07.2026
Outcome · 07 Jul 2026, 11:20 pm
Samsrita Labs Board Approves 50% Capital Reduction, Director Appointments Samsrita Labs' board on 4th Jul'26 approved a 50% reduction in paid-up equity share capital to ₹11.37 crore from ₹22.75 crore. This is to set off accumulated losses and improve the balance sheet. The company also appointed Ravi Kanth Chopperla as an Additional Non-Executive Director and Satyanarayana Murthy Varanasi as an Additional Independent Director, effective 4th Jul'26. Additionally, the board approved an alteration to its main object clause to enter the pet animal healthcare business and a related party transaction with QROPS Advisory Services.
Appointment of Mr. Ravi Kanth Pattabhi Chopperla as an Additional Director in the Category of Professional and Non-Executive
Change in Management · 04 Jul 2026, 9:55 pm
Samsrita Labs Board Approves Capital Reduction and Business Expansion The Board approved a scheme to reduce paid-up equity share capital by 50% from ₹22.75 crore to ₹11.37 crore to set off accumulated losses. It also approved altering its MOA to enter the pet animal healthcare and wellness business. A related party transaction with QROPS Advisory Services was proposed. Mr. Ravi Kanth Chopperla, holding a 7.1% stake, was appointed as a Non-Executive Additional Director, effective 04 Jul'26. The Annual General Meeting is scheduled for 10 Aug'26 to seek shareholder approvals.
Outcome of Board Meeting held on 04.07.2026
Others · 04 Jul 2026, 9:52 pm
Samsrita Labs Board Approves 50% Share Capital Reduction and New Business Vertical Samsrita Labs' board on 4th Jul'26 approved a 50% reduction in paid-up equity share capital to set off accumulated losses. The scheme will see paid-up capital fall from ₹22.75 Cr to ₹11.37 Cr via cancellation of shares on a pro-rata basis, subject to shareholder and NCLT approval. The board also approved altering its MOA to enter the pet healthcare and wellness business. Additionally, Mr. Ravi Kanth Chopperla, holding a 7.1% stake, was appointed as an Additional Director (Non-Executive).
Outcome of Board Meeting held on 04.07.2026
Outcome · 04 Jul 2026, 9:51 pm
Samsrita Labs Approves 50% Share Capital Reduction and Enters Pet Care Samsrita Labs' board on 04 Jul'26 approved a scheme for capital reduction, aiming to set off accumulated losses. The proposal involves cancelling 1.14 crore equity shares (50% of paid-up capital) on a pro-rata basis, reducing paid-up capital from ₹22.75 crore to ₹11.37 crore. The board also approved altering its MOA to enter the pet animal healthcare and wellness business. Additionally, Mr. Ravi Kanth Chopperla, holding a 7.1% stake, was appointed as an Additional Director. The AGM is scheduled for 10 Aug'26.
Samsrita Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/07/2026 ,inter alia, to consider and approve 1. To consider and draft scheme ....
Intimation · 04 Jul 2026, 5:30 am
Samsrita Labs Board to Consider Share Capital Reorganization on 04-Jul'26 Samsrita Labs (BSE: 539267) has scheduled a Board of Directors meeting on 04-Jul'26 to consider a draft scheme for the reorganization and rearrangement of the company's share capital. In connection with this meeting, the trading window for insiders will be closed from 30-Jun'26 until 48 hours after the meeting concludes. A separate trading window closure is also in effect from 01-Jul'26 until 48 hours after the declaration of financial results for the quarter ending 30-Jun'26.
Statement of deviation or variation for Q4 2025-26
Others (Uncategorized) · 29 May 2026, 10:37 pm
Samsrita Labs Confirms No Deviation in Use of Preferential Issue Proceeds for Q4 FY26 Samsrita Labs reported no deviation in the utilization of funds from its preferential issue for the quarter ended 31st Mar'26. The company raised ₹339.10 lakhs on 18th Jul'25. As of quarter-end, funds were utilized as per the original objectives: ₹52.10 lakhs for working capital, ₹88.31 lakhs for repayment of promoter loans, ₹34.32 lakhs for general corporate purposes, and ₹2.0 lakhs for new projects. The utilization was reviewed by the Audit Committee on 29th May'26, confirming compliance with stated goals.
Appointment of Internal Auditor for the F.Y 2026-27
Change in Management · 29 May 2026, 10:27 pm
Samsrita Labs Board Approves FY26 Results and Write-offs Samsrita Labs reported FY26 standalone net loss widened to ₹868.60 lakh from ₹25.95 lakh YoY. For Q4FY26, net loss was ₹11.87 lakh versus a loss of ₹8.70 lakh YoY. The Board, at its meeting on 29th May'26, also approved writing off ₹209 lakh in trade receivables and ₹3.15 lakh in sundry creditors. Additionally, M/s Tungala & Co. were appointed as internal auditors for FY27. Total standalone assets stood at ₹1,396.91 lakh as of 31st Mar'26, down from ₹1,567.92 lakh YoY.
outcome of board meeting held on 29.05.2026
Outcome · 29 May 2026, 10:09 pm
Samsrita Labs Board Approves FY26 Results, Write-Offs, and New Auditor Samsrita Labs board approved audited standalone and consolidated results for Q4 and FY ended 31st Mar'26. For FY26, the company reported a standalone net loss of Rs. 868.60 lakhs versus a loss of Rs. 25.95 lakhs YoY. The board also approved the write-off of Rs. 2.09 crore in trade receivables and Rs. 3.15 lakhs in sundry creditors. Additionally, M/s Tungala & Co., Chartered Accountants, were appointed as the internal auditors for FY 2026-27. Auditors issued an unmodified opinion on the financial results.
Audited Financial results (Standalone and Consolidated) for the quarter and year ended 31.03.2026
Financial Result · 29 May 2026, 10:05 pm
Samsrita Labs Ltd - Financial Result for the Quarter ended 31st Mar'26 (Consolidated, INR Lakh) ■ Revenue: 1.8 ■ EBITDA: -15.0 (+95.5% QoQ) ■ EBITDA Margin (%): -828 ■ PAT: -48.2 (+83.6% QoQ) ■ EPS (INR): -0.06 (+95.3% QoQ)